Clinical-stage biotech possibly nearing phase I completionNascent Biotech is reportedly closing in on phase I trial completion. I am interested to see if it pulls back and how it interacts with the moving averages.
www.nascentbiotech.com
Biotech
CRSP: Big orrection after the next rally, but buy-the-dip.I believe that CRSP (Crispr Therapeutics) is about to undergo a severe correction soon.
I scaled into this stock during the latter part of 2022 and the first part of 2023 and it is up nearly 70% and has generated about 40% of pure alpha for me relative to the SPX.
So this has been an amazing performer for my total portfolio.
I believe this run may be nearing a pullback and I expect the correction to be a very severe one.
My suggestion is that this will form a triple-bottom/inverse head-and-shoulders pattern because this will be a subwave 2 correction and in theory, it should not overthrow the recent low by very much.
I think the post-correction rally will be sizeable (it'll be a macro Wave 3) and the catalyst for this rally will be the steady trend of slowly improving earnings that they have demonstrated over the past year.
(3 successive quarters of positive earnings calls - this has not been achieved since 2017)
So, in essence, presuming nothing else changes, I believe we should buy the next dip for a significant Wave 3 rally that will exceed the all-time highs.
In the meantime, expect lots of volatility, if you don't have the stomach for taking drawdowns or losses in the interim, you may want to sell the next rally so that you can buy back in. I will probably pursue this course of action myself purely as a matter of greed to preserve the alpha I have managed to capture.
Happy biotech trading!
FLMD biotechology rising post earningsFLMD had earnings in May with positive earnings beating the expectation of analysts that
it would continue to lose quarter after quarter. Investors and traders have reacted with a
80% run-up in the month after those earnings. On the 30-minute chart besides the consistent
uptrend with minor corrections, what stands out for me is the increasing volumes relative
to volumes before the last earnings report. Off the chart, I find information that insider trading
with buying more shares on top of existing holdings leads me to believe that this company
expects increasing revenues and sustained earnings.
Hot News Trade!Based on Phase 2 data evaluation we could expect a positive outcome. Information sound good so far. THese kind of news often cause a wild rally on the day. Maybe two days. But generally they dont last long. Depends on the news of course.
But I would expect a pop on this on monday or tuesday. Maybe interesting for a short trade.
AUTL Is this a pump and dump?AUTL on the one-hour chart had a spontaneous parabolic move without a catalyst as best as
I can tell. Earnings ten days ago were decent but nothing special. AUTL as a biotech firm is
losing cash just not as much as analysts predicted. In the parabolic move very few shares
were traded between $2.00 and $2.40 as per the volume profile Overall a massive volume
occurred compared with the entire year although there was a bit in the runup to earnings.
I suspect a pump and dump and think it might be worth playing. Insiders could be
manipulating the shares and acting as a team. The zero-lag MACD suggests that the top has
been reached. I believe that insiders will be selling quickly and short sellers will be
joining in. I will be one of the latter. Retail buyers could be stuck bag holding if caught
by surprise. Once price drops to $4.00 the bearish momentum will kick in due to the
volume void on the profile. Accordingly, I will buy a group of call options when
AUTL hits $4.05 set a stop loss and await the flush back down to $2.00. If things go
well this will be over a 100% return on investment and 300% return on risk in one day.
The contracts for 6/16 ( $5.00) are about $250 with about 25% spread between the bid
and ask.
Pullback Buy in TGTXBiotech stocks can make huge moves, and this one is no exception.
TGTX more than doubled in a month and is showing no signs of slowing down.
Slower-trending, blue chip stocks tend to ride their 50-day moving average (red line on chart) on the way up.
Stronger stocks tend to hold their 21-day moving average (blue line).
But with high-flying honey badger stocks like TGTX, you are lucky to get a pullback to the 10-day (yellow line).
TGTX touched its 10-day exponential moving average on Friday, making this the first real pullback buying opportunity since the initial surge.
I would consider buying here with an 8-10% stop loss.
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked)
approximately a doubling of the shart price in the next year. Like many low share priced
biotechnology stocks the price is based on perceived future earnings which can be affected
by favorable FDA process, or well-received research at industry conferences and changing
financials within the company. In general, they have a low beta meaning these stocks are not
general market responsive and run on their own present or future merits.
On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal
into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two
days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green.
I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days
for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology
trades long with a high R:R due to the inheret risk level.
BLUE Biotechnology New Earnings Catalyst LONGBlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time
but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks
since earnings which is about 500% annualized. GO BLUE.
On the daily chart, price was above VWAP and consolidating much of last fall then dropped
this YTD until the earnings report of last week. An uptrend is seen after the earnings.
This has been a significant reversal sustained over the past month
with price rising above the support / demand zone below it. At present, price is one
standard deviation below VWAP making it undervalued and ascending.
I see this as a risky long trade like many biotechology penny stocks but with a decent
probability of profit in consideration of a target of 6.15 which is the top of the long
term high volume area. the stop loss is just below the POC line of the volume profile
at 3.15 An entry at 4.62 ( limit order above SMA200 (redlne) would yield at profit of
1.50 with a risk of 0.48 making for a R:R of 3:1. Another earnings report is coming up this
week. If it is favorable, BLUE could go parabolic to hit the target in a day or two.
If not, it will be time to exit the trade.
Cathie Wood is long BEAM, But I will be Strong Short #CathieWood
Baught this stock...I analyzed it....and …...well....I would do exact the opposite......
But why?
Technical Analysis
Let forget eveything you know about technical analysis, and let together tell this story....logically..
At
76-71 USD AGGRESSIVE SELLERS FORCED THE PICE DOWN
29,72 USD BUYERS DEFENDED THIS Area(ZONE) as well the sellers took partial profits, and accumulated their positions ,but this time more powerfully and aggressive at 64-61USD zone
THE PRICE MOVED DOWN, Institutional buyers took patial profits,(the best decision they could do OTHERWISE THEY WOULD LOSE ALL THIER PROFITS LOOK AT THE PICE OF TODAY
The retail traders who followed the news and the hype baught Beam hoping that the share prce will fly to the moon,but......
At 64-61 who is waiting there?
YES THE AGGRESSIVE SELLERS!!!!
NOW THEY FORCED MUCH MORE ORDERS TO SEND THE PRICE To the....where we are now....
Bad for the buyers...Some buyers took profits, some took losses, and to compensate thier losses, they started to sell short the market....
At 28,80(YELLOW LINE) we are now at the weak support(low volume) The market could make a retracement to 44,94USD
where the sellers and BEARS are waiting of them.....to do what? Well you know it.....
Otherwise...more selles (former retail trades bulls) could decide to sell the maket from here....
WE HAVE A LONG DISTANCE TO GO DEEPER....
Targets short
13,75
8,68
3,82
1,25
.
.
Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (BEAM 1.11%). The gene-editing stock currently ranks as the ETF's 18th-largest holding. It's also the ninth-largest position in Wood's ARK Genomic Revolution ETF.
Beam Therapeutics is a pioneer in base editing. Most types of gene editing involve double-strand breaks in DNA that can cause random unwanted insertions and deletions. Base editing is highly precise, with no double-strand breaks and no off-target genetic changes. Because of these characteristics, base editing holds tremendous promise as a method for developing therapies targeting genetic diseases and "off the shelf" cell therapies for treating cancer.
So far, Beam has advanced two base-editing candidates into clinical testing. It's evaluating BEAM-101 as a treatment for two rare blood disorders: sickle cell disease and beta-thalassemia. And the company expects to begin dosing patients in a phase 1 study of experimental cancer cell therapy BEAM-201 by mid-2023.
Those two programs could be joined by two others soon. Beam hopes to submit for regulatory approvals to start clinical studies of BEAM-301 as a treatment for glycogen storage disease type 1a and BEAM-302 as a treatment for severe alpha-1 antitrypsin deficiency by early 2024.
The company has a long way to go. But if its base-editing programs prove to be safe and effective, Beam could be a massive winner.
MRNA ? Buy Weakness MRNA descended this past winter off a head-and-shoulders pattern on the daily chart just under
the demand zone as shown by the LuxAlgo indicator. Price is now in a downtrend heading into
earnings tomorrow. MRNA needs to show something good otherwise it will break through the
demand zone and keep going down.
This is a risky earnings play betting that something will show up on the report to buoy up the
company and its stock. I will risk 0.01% of the trading account on a call option with DTE 5/19/23
looking for a minor surge and so a good quick profit.
( see also the link below)
LABU Triple Leveraged Biotech Sector ETFOn the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity.
On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving
the bullish momentum. Small-cap speculative biotech companies are in a growth mode right now no matter adverse economic conditions
for those yet to have any earnings. Big pharma is more concerned about federal attempts to further regulate prices than the economy.
On the volume profile, price has ascended to above the high volume trading area on the strength of buyer interest propelling the
momentum. Overall, this looks to be a decent long trade. The target is $ 9.00 the YTD high back in February.
PHARMALA BIOTECH HOLDINGS INC(#MDMA))Hi Dude
from now on i am going to scrutinize Canada Stock market Shares
for This post I Analyze MDMA Share
as Depicted in picture i suggest:
Entry:0.295
SL:0.245
TP= 1:7 but dont hurry and wait for breaking orange trendline
if you like please support by comment and share
GOSS Penny Biotechology SHORTGOSS is a biotechnology penny stock without earnings valued based on future earnings
potential based on a "pipeline" which is subject to a long timeline of FDA regulation.
On the 30 minute chart. price is shown as being in the overvalued area in the upper VWAP
band and well above the POC line of the long-range volume profile. The RSI indicator is
now showing a bearish divergence as the relative strength is weakening. Price has bounced
down from the resistance of the line representing two standard deviations above VWAP.
The supply / demand zones are indicated by the Indicator applied which is authored by
Luxalgo. Price has hit the supply zone lower border and is now in an early reversal.
I see this as a swing short trade also played with taking put options. Stop loss is
in the upper area of the red supply zone. Targets include first the POC line of the volume
profile and then a final target at one STD below VWAP also being just above the demand zone.
Alternatively put options at the strike of $ 1.50 for the May monthly expiration of 5/18
This trade will benefit from any expected pullback in the general markets.
$CABA Righty Tighty- Massive move 2,000%+
- Obeyed 20 MA for entire move
- Sitting back on 20 MA
- High ADR
- Tight right side
- Biotech
LABD 3X BEAR BIOTECH LONG DAYTRADEAs shown on the 15-minute chart, LABD is bouncing between stardard deviations of the VWAP in a 6% price range
fluctuation day to day. At the upper end it is reversing at the POC of the volume profile confluent with one
standard deviation above VWAP while at the bottom it is bouncing from the bottom of the lower high volume area
of the profile and two standard deviations below VWAP. I see this as an opportunity for a 6% upside long day
trade especially if the general market is uptrending after the weekend. Alternatively, a 5 DTE call option
with a strike of $ 15.50 or $16.00 looking for a 30-40% return on the premium over the upcoming week. ( The
zero lag MACD confirms the buy signal.)
ACHV a Biotech company after earningsACHV on the 4H seems to be demonstrating a "High Bull Flag Pattern"
after a big uptrend to start the year. Earnings on Thursday 3/16 were
quite favorable.On the relative volume indicator Friday, May 17th
showed a paradoxical huge selling volume spike to finish out this week.
( I mislabelled this as upcoming on the chart)
Paradoxically, the last earnings report in November was poor but
resulted in strong upward price action.
The MACD histogram is at the zero line.
Will ACHV resume the uptrend after earnings? Was the selling volume
an institutional trader fake out to set up a lower price to buy call options?
According to Tip Ranks, the analysts give ACHV a high rating with significant
upside. See the link below Who knows but this may be worth watching for signs of
buying volume and accumulation to fuel bullish momentum.
SIGA a Biotech breakout last summer- then breakdown ? reversalAs shown on the daily chart dating back to last summer SIGA has been on a persistent decline since the cooling down from the parabolic
breakout last summer. Is there a repeat in the picture? Fundamentally, earnings continue to be weak. much of the stock is held by insiders and
the whole monkey pox thing is settled down although the main product may have use in malaria, leper's disease or whatever other orphan use
it has indications by the FDA and its foreign counterparts.
The technical picture is that it is sitting just above support shown by the Supply Demand Zone indicator of Luxalgo having double bottomed
and now a bit above it. The volume indicator shows a mild increase in buying volume in the past couple of weeks. Price is more than one
standard deviation below the long-term anchored VWAP in the undervalued over-sold zone.
With a weak biotechnology company where insiders have a fair portion of the shares, manipulation can occur. Once a price rise issues
short sellers will buy to cover, and retail traders will jump on board, insiders will "manufacture" a catalyst to prime the pump further.
At some point, the run-up will stall, and the implode itself. I will get on the ride early, a biotechnology speculative trades are
in my playbook. The stop loss here is below the demand zone while the target is the 50% retracement of the downtrend drawn onto
the chart by the Fibonacci Retracement tool.
$KPTI: Low risk buy signalNice setup in $KPTI, I suggest buying these names with small positions considering the volatility that can occur after catalysts when new data is released, or around FDA approvals, etc.
Upside can be substantial though, so if technicals and fundamentals align, it's worth keeping some exposure.
Best of luck!
Cheers,
Ivan Labrie.
EYPT EyePoint Pharmaceutics LONGEYPT is now on another breakout on the 2h chart similar to what occurred
from mid-December to mid-January. On the indicators the MACD shows
the K/D lines on a steep upward slope. For me, what set off my interest
was a relative volume scan that produced this stock on the list.
The relative volume this week and consequential accumulation triggered
the breakout with those volume spikes
Fundamentally, EYPT had a catalyst as it completed one phase of its
FDA clinical trials for a treatment for macular degeneration, a
debilitating eye disease of the elderly. The potential market
is several multiples of the stock's current market cap.
This company is a takeover candidate as it is young without
a big pipeline but with upside potential.
The relative volume of 4X to 8X is a sure sign that buying
pressure will move the price. Price has crossed the SMA50 just as it
did last winter. The price is up 40% or more this week. Could this be
a pump and dump? Maybe. For sure it is a speculation play just like many
NASDAQ penny biotech stocks For mem the price action of last winter
with a 120% gain in one month is reassurance for this time around
with some hopeium thrown into the mix with the technical analysis.
I will buy a call option under the current price with the 4/21
expiration and leverage the speculation a bit. In the past day,
this option rose 67% based on the price surge of the underlying stock.
DYN - Falling WedgeOn the chart, we can se a falling wedge occurring.
The stock has held its strong support for a long period of time, and we are now expecting it to go to the upside after bullish consolidation.
MACD seems to make either a consolidating or bullish crossing.
Our first target is based on the forming, while the second target hits our resistance level.
Good luck!
Harvard Bioscience: Bouncing Higher From Multiple-Year SupportI zoomed all the way out to the monthly chart to show the long-term support levels. We can see that HBIO is bouncing higher from a multi-year support level in the $2 range. The MACD (middle of the chart) didn't confirm an upward trend yet. However, the MACD did confirm the upward trend on the weekly chart. It looks like the blue monthly MACD line is close to crossing above the red signal line. The purple RSI line on the bottom of the chart is pointing upward, which is bullish. This indicates that we could see a long-term continuation of the rally which began in December/January. Click on the link below for a detailed article. HBIO has a low valuation with strong expected EPS growth. This is likely to drive the stock higher IMO.
